文献速递泌尿男性生殖肿瘤妇科肿瘤胸部肿瘤

仑伐替尼联合帕博利珠单抗治疗晚期肾细胞癌、子宫内膜癌及其他晚期实体瘤的Ib/II期试验

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
PubMed 文献 · J Clin Oncol · 2020-01-21

该Ib/II期研究评估仑伐替尼联合帕博利珠单抗在晚期肾细胞癌、子宫内膜癌、头颈鳞癌、黑色素瘤、非小细胞肺癌和尿路上皮癌中的剂量与疗效。Ib期确定最大耐受剂量为仑伐替尼20 mg/d联合帕博利珠单抗,II期扩展显示第24周客观缓解率在肾细胞癌为63%、子宫内膜癌52%、黑色素瘤48%、头颈鳞癌36%、非小细胞肺癌33%、尿路上皮癌25%。

要点

  • 最大耐受剂量及II期推荐剂量为仑伐替尼20 mg/d联合帕博利珠单抗。
  • 肾细胞癌第24周客观缓解率最高,达63%。
  • 常见治疗相关不良事件为疲劳、腹泻、高血压和甲状腺功能减退。

核心结论

  • 仑伐替尼联合帕博利珠单抗在所选晚期实体瘤中显示出可控的安全性和有前景的抗肿瘤活性。

研究设计与样本

  • Ib/II期研究,Ib期入组13例,初始II期扩展入组124例,共137例患者。
  • Ib期主要目标为确定仑伐替尼联合帕博利珠单抗(200 mg静脉每3周)的最大耐受剂量。
  • II期扩展主要目标为在II期推荐剂量下评估第24周客观缓解率。

主要发现

  • 初始剂量水平(仑伐替尼24 mg/d联合帕博利珠单抗)报告2例剂量限制性毒性:3级关节痛和3级疲劳。
  • 后续降剂量队列未观察到剂量限制性毒性,确定最大耐受剂量和II期推荐剂量为仑伐替尼20 mg/d联合帕博利珠单抗。
  • 第24周客观缓解率:肾细胞癌63%(19/30;95% CI,43.9%至80.1%)。
  • 第24周客观缓解率:子宫内膜癌52%(12/23;95% CI,30.6%至73.2%)。
  • 第24周客观缓解率:黑色素瘤48%(10/21;95% CI,25.7%至70.2%);头颈鳞癌36%(8/22;95% CI,17.2%至59.3%);非小细胞肺癌33%(7/21;95% CI,14.6%至57.0%);尿路上皮癌25%(5/20;95% CI,8.7%至49.1%)。

关键数值与推荐

  • 仑伐替尼II期推荐剂量为20 mg/d,联合帕博利珠单抗200 mg静脉每3周。
  • 最常见治疗相关不良事件:疲劳58%、腹泻52%、高血压47%、甲状腺功能减退42%。

临床怎么用

  • 在晚期肾细胞癌、子宫内膜癌等所选实体瘤中,可考虑仑伐替尼20 mg/d联合帕博利珠单抗治疗。
  • 治疗期间需监测疲劳、腹泻、高血压和甲状腺功能减退等常见不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Modulation of vascular endothelial growth factor-mediated immune suppression via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We report results from the dose-finding and initial phase II expansion of a phase Ib/II study of lenvatinib plus pembrolizumab in patients with selected advanced solid tumors. METHODS: Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), melanoma, non-small-cell lung cancer (NSCLC), or urothelial cancer. The primary objective of phase Ib was to determine the maximum tolerated dose (MTD) for lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks). In the preplanned phase II cohort expansion, the primary objective was objective response rate at week 24 (ORRweek 24) at the recommended phase II dose. RESULTS: Overall, 137 patients were enrolled during phase Ib (n = 13) and the initial phase II expansion (n = 124). Two dose-limiting toxicities (DLTs; grade 3 arthralgia and grade 3 fatigue) were reported in the initial dose level (lenvatinib 24 mg/d plus pembrolizumab). No DLTs were observed in the subsequent dose-de-escalation cohort, establishing the MTD and recommended phase II dose at lenvatinib 20 mg/d plus pembrolizumab. ORRweek24 was as follows: RCC, 63% (19/30; 95% CI, 43.9% to 80.1%); endometrial cancer, 52% (12/23; 95% CI, 30.6% to 73.2%); melanoma, 48% (10/21; 95% CI, 25.7% to 70.2%); SCCHN, 36% (8/22; 95% CI, 17.2% to 59.3%); NSCLC, 33% (7/21; 95% CI, 14.6% to 57.0%); and urothelial cancer 25% (5/20; 95% CI, 8.7% to 49.1%). The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%). CONCLUSION: Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Taylor MH, Lee CH, Makker V, et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020. PMID: 31961766. doi:10.1200/JCO.19.01598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。